BTK and B-cell chronic lymphocytic leukemia: The development of inhibitors of B-cell receptor (BCR) signalling, particularly those that inhibit Bruton tyrosine kinase (BTK), has transformed the treatment landscape for chronic lymphocytic leukaemia (CLL) over the last decade.